{
  "abstract": "To our knowledge, clinically meaningful restoration of radioiodine avidity in established radioiodine-refractory differentiated thyroid cancer has not been reported after multikinase inhibitor therapy, despite successful redifferentiation reported with selective kinase inhibitors targeting BRAF, RAS, RET or NTRK. We report a 53-year-old woman with invasive follicular variant papillary thyroid carcinoma and synchronous cervical lymph node, pulmonary and bone metastases who underwent six cycles of radioiodine therapy within 3 years after total thyroidectomy. Initially radioiodine-avid metastases gradually lost radioiodine avidity, as suggested by serial post-radioiodine therapy whole-body scans. Lenvatinib was initiated after 3 years of active surveillance. Restored radioiodine uptake was observed on rhTSH-assisted diagnostic whole-body scan after 9 months of lenvatinib treatment, allowing subsequent salvage radioiodine therapy. Subsequent post-radioiodine therapy whole-body scans showed increased uptake intensity and additional radioiodine-avid bone metastases, with a marked decrease in suppressed thyroglobulin. Reassessment of radioiodine avidity after prolonged multikinase inhibitor treatment warrants clinical consideration to determine the feasibility of salvage radioiodine therapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China.",
    "Department of Nuclear Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, Shandong, China.",
    "Department of Nuclear Medicine Center, Beijing Nuclear Industry Hospital, Beijing, China.",
    "Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. linys@pumch.cn."
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Kexu Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Yihan Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Cong Shi"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Zheng Li"
    },
    {
      "affs": [
        3
      ],
      "name": "Yansong Lin",
      "orcid": "0000-0001-6095-4728"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fmebrqcrpdtvp.bib",
  "cited_by": 0,
  "doi": "10.1186/s41824-026-00334-3",
  "fulltext_url": "https://europepmc.org/articles/PMC13719981",
  "id": "fmebrqcrpdtvp",
  "issns": [
    "3005-074X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42957933",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Case Report"
    ],
    [
      "openalex",
      "2712|Thyroid Cancer Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7224299561",
  "pdf_url": "https://europepmc.org/articles/PMC13719981?pdf=render",
  "pmcid": "PMC13719981",
  "pmid": "42957933",
  "published": "2026-10-30",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/fmebrqcrpdtvp.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T00:20:36Z",
      "native_id": "MED:42957933",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42957933"
    },
    {
      "first_seen": "2026-11-02T12:23:51Z",
      "native_id": "PMC13719981",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s41824-026-00334-3"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Thyroid Cancer Diagnosis and Treatment",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Restoration of radioiodine avidity after lenvatinib in NRAS- and TERT promoter-mutant radioiodine-refractory differentiated thyroid cancer: a case report.",
  "title_text": "Restoration of radioiodine avidity after lenvatinib in NRAS- and TERT promoter-mutant radioiodine-refractory differentiated thyroid cancer: a case report.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:20:57Z",
  "url": "https://research.draconitic.com/paper/fmebrqcrpdtvp",
  "venue": "EJNMMI reports",
  "versions": []
}